We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MorphoSys Strengthens Patent Position on its Core Technologies in Japan
News

MorphoSys Strengthens Patent Position on its Core Technologies in Japan

MorphoSys Strengthens Patent Position on its Core Technologies in Japan
News

MorphoSys Strengthens Patent Position on its Core Technologies in Japan

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys Strengthens Patent Position on its Core Technologies in Japan"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MorphoSys AG has announced that the Japanese Patent Office has granted a new patent covering its CysDisplay® technology. CysDisplay® is a proprietary screening technology, which is an important component of MorphoSys's proprietary HuCAL platform.

The new patent (JP 4312403) entitled "Novel Methods for Displaying (Poly) Peptides/Proteins on Bacteriophage Particles" describes a selection technology based on phage display for selecting high affinity antibodies.

The claims are not limited to the use of a HuCAL library with this selection technology. Additional applications, including continuation applications, are currently pending in different countries.

"This new patent expands the protection of our proprietary core technology HuCAL in Asia. Over the last few years we have built a strong intellectual property portfolio around our proprietary technology HuCAL, which lies at the heart of our successful partnership-based business model. We expect to continue to strengthen still further our IP position in this important market for antibody-based products and services," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.

MorphoSys's HuCAL libraries are collections of diverse, fully human synthetic antibodies, whose modular CDR designs facilitate systematic engineering of antibody properties. The company's most advanced marketed version, HuCAL PLATINUM, provides access to fully human antibodies as research tools, diagnostics and therapeutics.
Advertisement